PPARγ agonists provided neuroprotection in the MPTP (Breidert et al., 2002; Dehmer et al., 2004; Lecca et al., 2015; Pisanu et al., 2014; Barbiero et al., 2014) and 6-hydroxydopamine (6-OHDA) model of PD (Laloux et al., 2012; Sadeghian et al., 2012). The gene discussed is PPARG; the disease is Parkinson disease.